Breast Cancer, Cardiotoxicity, Chemotherapy Induced Systolic Dysfunction
Conditions
Brief summary
With this study the investigators will assess early cardiac damage by means of Global Longitudinal Strain (GLS) in newly diagnosed breast cancer (BC) patients treated with anthracycline-based chemotherapy, and to investigate whether myocardial damage as measured with T1 / T2 Cardiovascular Magnetic Resonance (CMR) mapping and plasma hs-Troponin T is related to changes in GLS.
Interventions
DIAGNOSTIC_TESTCMR
GLS measurement with CMR
Sponsors
Radboud University Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Female * Age ≥ 18 years * A diagnosis of primary breast cancer * Starting (neo-) adjuvant chemotherapy treatment within 2 months after screening * Cardiotoxicity risk score of intermediate, high or very high risk
Exclusion criteria
* Previous radiotherapy or systemic cancer treatment * Cancer metastasis * Life expectancy of less than 6 months * History of myocardial infarction or heart failure * Known contra-indications for CMR * Refusal or inability to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Global Longitudinal Strain (GLS) change after chemotherapy compared to baseline | Baseline and 2 weeks after the last chemotherapy cycle | A relative reduction in Global Longitudinal Strain (GLS) assessed with CMR |
Countries
Netherlands
Contacts
Primary ContactYvonne Koop, MSc
Outcome results
None listed